ABSI Nov 2024 5.000 call
| Previous Close | 1.2000 |
| Open | 0.0500 |
| Bid | 0.6500 |
| Ask | 1.1500 |
| Strike | 5.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 0.0500 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 581 |
- GuruFocus.com
Absci Corp (ABSI) Q1 2024 Earnings Call Transcript Highlights: Strategic Advancements and ...
Explore key financial outcomes, strategic partnerships, and innovative developments from Absci Corp's first quarter of 2024.
GlobeNewswireAbsci Reports Business Updates and First Quarter 2024 Financial and Operating Results
Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024. "During the first quarter, we made significant strides in advancing both our internal and partnered programs according to plan," said Sean McC
ZacksAbsci (ABSI) to Report Q1 Earnings: Here's What to Expect
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
